{"id":"https://openalex.org/W2018010993","doi":"https://doi.org/10.2217/fca.14.82","title":"ODYSSEY MONO: Effect of Alirocumab 75 Mg Subcutaneously Every 2 Weeks As Monotherapy Versus Ezetimibe Over 24 Weeks","display_name":"ODYSSEY MONO: Effect of Alirocumab 75 Mg Subcutaneously Every 2 Weeks As Monotherapy Versus Ezetimibe Over 24 Weeks","alternate_titles":[],"publication_year":2015,"publication_date":"2015-01-01","ids":{"openalex":"https://openalex.org/W2018010993","doi":"https://doi.org/10.2217/fca.14.82","mag":"2018010993","pmid":"https://pubmed.ncbi.nlm.nih.gov/25606700"},"language":"en","primary_location":{"id":"doi:10.2217/fca.14.82","doi":"https://doi.org/10.2217/fca.14.82","is_oa":false,"landing_page_url":"https://doi.org/10.2217/fca.14.82","pdf_url":null,"source":{"id":"https://openalex.org/S48687829","display_name":"Future Cardiology","issn_l":"1479-6678","issn":["1479-6678","1744-8298"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","ki-jl-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future Cardiology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2018010993"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5089409959","display_name":"Eli M. Roth","orcid":"https://orcid.org/0000-0002-3367-5704","observed_orcids":["https://orcid.org/0000-0002-3367-5704"]},"institutions":[{"id":"https://openalex.org/I4210090186","display_name":"Sterling Research Group","ror":"https://ror.org/009prea33","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210090186"]},{"id":"https://openalex.org/I63135867","display_name":"University of Cincinnati","ror":"https://ror.org/01e3m7079","country_code":"US","type":"education","lineage":["https://openalex.org/I63135867"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Eli M Roth","raw_affiliation_strings":["University of Cincinnati & Sterling Research Group, 375 Glensprings Drive, 2nd Floor, Cincinnati, OH 45246, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Cincinnati & Sterling Research Group, 375 Glensprings Drive, 2nd Floor, Cincinnati, OH 45246, USA","institution_ids":["https://openalex.org/I4210090186","https://openalex.org/I63135867"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5054320288","display_name":"James M. McKenney","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I184840846","display_name":"Virginia Commonwealth University","ror":"https://ror.org/02nkdxk79","country_code":"US","type":"education","lineage":["https://openalex.org/I184840846"]},{"id":"https://openalex.org/I4210126592","display_name":"National Clinical Research","ror":"https://ror.org/03ddkvp86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210126592"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"James M McKenney","raw_affiliation_strings":["Virginia Commonwealth University & National Clinical Research, Inc., 2809 Emerywood Parkway, Suite 140, Richmond, VA 23294, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Virginia Commonwealth University & National Clinical Research, Inc., 2809 Emerywood Parkway, Suite 140, Richmond, VA 23294, USA","institution_ids":["https://openalex.org/I184840846","https://openalex.org/I4210126592"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":8.1552,"has_fulltext":false,"cited_by_count":73,"citation_normalized_percentile":{"value":0.98247672,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":91,"max":100},"biblio":{"volume":"11","issue":"1","first_page":"27","last_page":"37"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13430","display_name":"Lipid metabolism and disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11618","display_name":"Cholesterol and Lipid Metabolism","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alirocumab","display_name":"alirocumab","score":1.0},{"id":"https://openalex.org/keywords/ezetimibe","display_name":"ezetimibe","score":0.972000002861023},{"id":"https://openalex.org/keywords/pcsk9-inhibition","display_name":"PCSK9 inhibition","score":0.9240000247955322},{"id":"https://openalex.org/keywords/ldl-cholesterol-lowering","display_name":"LDL cholesterol lowering","score":0.8349999785423279},{"id":"https://openalex.org/keywords/high-intensity-statin-therapy","display_name":"high-intensity statin therapy","score":0.6899999976158142},{"id":"https://openalex.org/keywords/lipid-lowering-therapy","display_name":"lipid-lowering therapy","score":0.6940000057220459}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9591705799102783},{"id":"https://openalex.org/C2778657065","wikidata":"https://www.wikidata.org/wiki/Q417997","display_name":"Ezetimibe","level":3,"score":0.925357460975647},{"id":"https://openalex.org/C2780902209","wikidata":"https://www.wikidata.org/wiki/Q4726914","display_name":"Alirocumab","level":5,"score":0.8535712361335754},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5151625871658325},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.39938950538635254},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3880915641784668},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.32139885425567627},{"id":"https://openalex.org/C2776839432","wikidata":"https://www.wikidata.org/wiki/Q954845","display_name":"Statin","level":2,"score":0.23876717686653137},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.1360704004764557},{"id":"https://openalex.org/C2994423189","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Total cholesterol","level":3,"score":0.11089932918548584},{"id":"https://openalex.org/C2780745583","wikidata":"https://www.wikidata.org/wiki/Q1316030","display_name":"Apolipoprotein A1","level":4,"score":0.0}],"mesh":[{"descriptor_ui":"D000069438","descriptor_name":"Ezetimibe","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000924","descriptor_name":"Anticholesteremic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D001384","descriptor_name":"Azetidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006937","descriptor_name":"Hypercholesterolemia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008078","descriptor_name":"Cholesterol, LDL","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.2217/fca.14.82","doi":"https://doi.org/10.2217/fca.14.82","is_oa":false,"landing_page_url":"https://doi.org/10.2217/fca.14.82","pdf_url":null,"source":{"id":"https://openalex.org/S48687829","display_name":"Future Cardiology","issn_l":"1479-6678","issn":["1479-6678","1744-8298"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","ki-jl-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future Cardiology","raw_type":"journal-article"},{"id":"pmid:25606700","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25606700","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future cardiology","raw_type":"Clinical Trial, Phase III"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":21,"referenced_works":["https://openalex.org/W1974768421","https://openalex.org/W1989730880","https://openalex.org/W2010033213","https://openalex.org/W2019071303","https://openalex.org/W2035511692","https://openalex.org/W2040612932","https://openalex.org/W2059870401","https://openalex.org/W2059881177","https://openalex.org/W2067539811","https://openalex.org/W2096075279","https://openalex.org/W2101702589","https://openalex.org/W2107165713","https://openalex.org/W2123341306","https://openalex.org/W2127791131","https://openalex.org/W2139575534","https://openalex.org/W2148577580","https://openalex.org/W2165624352","https://openalex.org/W2168483013","https://openalex.org/W2417850928","https://openalex.org/W3031812472","https://openalex.org/W7015805843"],"related_works":["https://openalex.org/W2101702589","https://openalex.org/W2985327235","https://openalex.org/W2726233376","https://openalex.org/W2321563682","https://openalex.org/W3040268455","https://openalex.org/W2417076517","https://openalex.org/W2153898283","https://openalex.org/W2141898196","https://openalex.org/W2588974371","https://openalex.org/W4415451063"],"abstract_inverted_index":{"ABSTRACT":[0],"Alirocumab":[1],"is":[2],"a":[3,23,35,98,109],"fully":[4],"human":[5],"monoclonal":[6],"antibody":[7],"to":[8,21,49,84],"PCSK9.":[9],"The":[10],"ODYSSEY":[11],"MONO":[12],"study":[13,20],"was":[14],"the":[15,88,93,132],"first":[16],"alirocumab":[17,50,68,94],"Phase":[18],"III":[19],"test":[22],"previously":[24],"unused":[25],"dose":[26,69],"of":[27,43,119],"75":[28,53],"mg":[29,54,62],"subcutaneously":[30,55],"every":[31,56,65],"2":[32,57],"weeks":[33,58,73],"in":[34,105],"population":[36],"on":[37,75],"no":[38],"lipid-lowering":[39],"therapy.":[40],"A":[41],"total":[42],"103":[44],"patients":[45],"were":[46,129],"randomly":[47],"assigned":[48],"starting":[51],"at":[52,71,79],"or":[59],"ezetimibe":[60,115],"10":[61],"per":[63],"os":[64],"day":[66],"with":[67,108,114],"uptitration":[70],"12":[72],"based":[74],"achieved":[76],"LDL-cholesterol":[77,106],"level":[78],"week":[80,85],"8":[81],"and":[82,126],"followed":[83],"24.":[86],"At":[87],"week-24":[89],"primary":[90],"end":[91],"point,":[92],"intent-to-treat":[95],"group":[96],"showed":[97],"47.2%":[99],"(least":[100],"square":[101],"[LS]":[102],"mean)":[103,112],"reduction":[104,113],"compared":[107],"15.6%":[110],"(LS":[111,116],"mean":[117],"difference":[118],"31.6%;":[120],"p":[121],"<":[122],"0.0001).":[123],"Safety":[124],"parameters":[125],"adverse":[127],"events":[128],"similar":[130],"between":[131],"two":[133],"groups.":[134]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2018010993","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":9},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":8},{"year":2017,"cited_by_count":8},{"year":2016,"cited_by_count":20},{"year":2015,"cited_by_count":5}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
